ArticleBMC pregnancy and childbirth2026
ELABELA targets the METTL3/PI3K/AKT axis to enhance trophoblast invasion in early-onset preeclampsia.
Article in BMC pregnancy and childbirth, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundEarly-onset preeclampsia (EOPE) is a serious condition characterized by dysregulated trophoblast Invasiveness, leading to inadequate reconstruction of uterine spiral arteries and shallow placental implantation. ELA is a recently discovered protein which serves as an endogenous ligand of the angiotensin receptor AT1-related receptor protein(APJ). It has been found to have high cross species conservation and high expression in the placenta, indicating that it may play an important physiological role in pregnancy. This study aimed to evaluate the role of ELA in the context of EOPE and its impact on trophoblast function.
methodsPlacental tissue samples from normal pregnancies, preterm births, and EOPE cases were analyzed for ELA expression in cytotrophoblasts and syncytiotrophoblasts. Levels of ELA and APJ were measured and compared among the different groups. Additionally, HTR-8/SVneo cells were utilized to assess the functional effects of ELA silencing and overexpression on cell migration and invasion. The involvement of the METTL3/PI3K/AKT signaling pathway was also investigated through the knockdown of METTL3.
resultsWhile the mRNA and protein levels of ELA and APJ showed no significant changes between normal pregnancies and preterm births, significantly lower ELA and APJ levels were observed in samples from the EOPE group compared to those from normal pregnancies. Silencing ELA in HTR-8/SVneo cells led to compromised migratory and invasive potential, accompanied by decreased levels of key kinases associated with the METTL3/PI3K/AKT pathway. Conversely, ELA overexpression resulted in enhanced migration and invasion. Additionally, knockdown of METTL3 inhibited cell migration and invasion, correlating with reduced kinase levels within the same signaling pathway.
conclusionOur findings indicate that ELA plays a crucial role in stimulating trophoblastic cell migratory and invasive activities through the activation of METTL3/PI3K/AKT signaling. This suggests that dysregulation of ELA could contribute to the pathogenesis of EOPE. The results highlight potential avenues for developing novel therapeutic strategies for this serious condition. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.